



Dedicated to research for
drug efficacy and safety



Nextcea, Inc.

A pharmaceutical service company dedicated to optimizing efficacy, minimizing toxicity, and ensuring the quality of drug products.

Company Overview

Nextcea, Inc. is a drug development service company dedicated to optimizing efficacy and minimizing toxicity in all phases of drug development. Nextcea integrates non-GLP and GLP/GCP LC-MS/MS biomarker quantitation with PK/PD for efficacy and TK/TD for safety assessments. Our in-house technology platforms include UPLC-MS/MS (QTOF X500Bs, API-6500s, and TripleTOF 6600s). We perform proteomic and lipidomic analyses using advanced bioinformatics (MarkerView and ProteinPilot).



Biomarkers for Drug Efficacy & Safety Assessment

Biomarker discovery/development and quantitation for pharmaceutical research. Identification of new therapeutic uses to reduce risk in pharmaceutical pipelines.



Autophagy-Lysosomal Disorders

(Drug-Induced Phospholipidosis (DIPL) and Parkinsonism, Parkinson's disease)

Nextcea's patented di-22:6-BMP for non-invasive monitoring of DIPL and Parkinsonism. Evaluate autophagy-lysosomal function in Parkinson's disease to identify new therapies.



Biotherapeutics


Sequence and structural analyses of biotherapeutic antibodies/ADCs. LC-MS/MS quantitation of biotherapeutics through all phases of drug development.



DMPK/ADME

A range of non-GLP/GLP PK services and drug metabolism assays.

Nextcea, Inc. • 500 W. Cummings Park • Suite 4550 • Woburn, MA 01801 • USA

tel: 800-225-1645 •  inform@nextcea.com •  hiro.mimura@nextcea.com

www.nextcea.com